Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Strata Critical Medical (SRTA) Revenue (2020 - 2025)

Historic Revenue for Strata Critical Medical (SRTA) over the last 6 years, with Q3 2025 value amounting to $49.3 million.

  • Strata Critical Medical's Revenue rose 3670.35% to $49.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $312.7 million, marking a year-over-year increase of 5402.49%. This contributed to the annual value of $248.7 million for FY2024, which is 1044.19% up from last year.
  • According to the latest figures from Q3 2025, Strata Critical Medical's Revenue is $49.3 million, which was up 3670.35% from $70.8 million recorded in Q2 2025.
  • In the past 5 years, Strata Critical Medical's Revenue registered a high of $138.3 million during Q4 2024, and its lowest value of $9.3 million during Q1 2021.
  • In the last 5 years, Strata Critical Medical's Revenue had a median value of $45.7 million in 2022 and averaged $47.7 million.
  • As far as peak fluctuations go, Strata Critical Medical's Revenue surged by 27670.16% in 2021, and later crashed by 4952.27% in 2024.
  • Strata Critical Medical's Revenue (Quarter) stood at $24.6 million in 2021, then skyrocketed by 54.91% to $38.1 million in 2022, then increased by 24.5% to $47.5 million in 2023, then soared by 191.22% to $138.3 million in 2024, then tumbled by 64.35% to $49.3 million in 2025.
  • Its last three reported values are $49.3 million in Q3 2025, $70.8 million for Q2 2025, and $54.3 million during Q1 2025.